SMi are proud to announce that registration is now live for the 7th annual COPD conference, taking place on the 19th & 20th October 2015 in London UK.

LONDON, ENGLAND, UNITED KINGDOM, June 11, 2015 /EINPresswire.com/ -- SMi's 7th annual conference on COPD will bring together respiratory leaders and scientific pioneers to strengthen knowledge in combinational therapies, new drugs and personalised treatment, whilst keeping attendees at the forefront of scientific breakthroughs to adapt to the growing need for efficiency in the management of exacerbations.

Understanding COPD pulmonary indications through biomarkers and the practicalities of reliable clinical trials will be a major focus as will hearing from a selection of pharmaceutical organisations currently developing scientific trials for COPD includes case studies from Novartis, Mundipharma, Janssen, MedImmune and Bayer.

Key Speakers Include:

• Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG
• Philip Silkoff, Senior Medical Director, Johnson and Johnson Pharmaceutical Services LLC
• Stefano Petruzzelli, Chief Medical Officer and Director, Global Clinical Development, Chiesi Farmaceutici S.p.A
• Sanjeeva Dissanayake, Head of Medical Sciences – Respiratory, Mundipharma
• Noel Snell, Director of Research, British Lung Foundation
• Geoff Down, Chief Medical Officer, Prosonix
• Konstantinos Kostikas, Medical Director Respiratory COPD Region Europe, Novartis Pharma
• Thomas Schlange, Senior Biomarker Expert, Bayer
• Matthew Sleeman, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune

Key Benefits of Attending Include:

• Gain insight into formulation developments and the manufacturing of dry powder inhalation products
• Evaluate COPD and comorbidities
• Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
• Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
• Study the role of lymphoid follicles in COPD Novel delivery and formulation methods
• Analyse airway disease endotyping for personalized therapeutics

In addition to the conference there will be an interactive workshop entitled Improving probability of success in COPD drug development, taking place on the 21st October at the Holiday Inn Regents Park Hotel in Central London.

The workshop will be hosted by: Dr. Graham Clarke, Senior Director and Head of Respiratory & Inflammation at the Early Clinical Development unit, Quintiles and Dr Juan Gispert, European Head allergy, Respiratory, infectious Diseases, Vaccines, Medical Science & Strategy, Quintiles

For those who are interested in attending there is currently a £300 early bird rate available online. For more information or to register visit www.copd-conference.co.uk/ein

Sponsored by Quintiles

COPD
19th & 20th October 2015
Holiday Inn Regents Park Hotel, London UK
www.copd-conference.co.uk/ein

---END---

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group Ltd
+442078276162
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.